Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The combination of cyclin-dependent kinase (CDK) 4/6 inhibitors with endocrine therapy is the standard treatment for patients with HR+/HER2- advanced breast cancer. Recently, this combination has also entered the early setting as an adjuvant treatment in patients with HR+/HER2- disease at a high risk of disease recurrence following (neo)adjuvant chemotherapy. Despite their current use in clinical practice, limited data on the potential gonadotoxicity of CDK4/6 inhibitors are available. Hence, fully informed treatment decision making by premenopausal patients concerned about the potential development of premature ovarian insufficiency and infertility with the proposed therapy remains difficult. The cell cycle progression of granulosa and cumulus cells is a critical process for ovarian function, especially for ensuring proper follicular growth and acquiring competence. Due to the pharmacological properties of CDK4/6 inhibitors, there could be a potentially negative impact on ovarian function and fertility in women of reproductive age. This review aims to summarize the role of the cyclin D-CDK4 and CDK6 complexes in the ovary and the potential impact of CDK4/6 inhibition on its physiological processes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605229 | PMC |
| http://dx.doi.org/10.3390/cancers15204923 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Medication-Related Osteonecrosis of the Jaw induced by a CDK 4/6 inhibitor (Palbociclib) in a patient who was naïve to Antiresorptive Bone Therapy: A Case Report.
Oral Surg Oral Med Oral Pathol Oral Radiol
August 2025
Service d'Odontologie, CHU Clermont-Ferrand, Clermont-Ferrand, France; Université Clermont Auvergne, CHU Clermont-Ferrand, INSERM, Neuro-Dol, Clermont-Ferrand, France. Electronic address:
Medication-related osteonecrosis of the jaw (MRONJ) is a well-documented adverse effect initially linked to antiresorptive agents such as bisphosphonates. Over time, other drug classes have been associated with MRONJ: monoclonal antibodies targeting RANK ligand, monoclonal antibodies targeting VEGF, tyrosine kinase inhibitors, and mammalian target of rapamycin (mTOR) inhibitors. This article presents the case of an 83-year-old female patient referred to the maxillofacial surgery department due to a submental cutaneous fistula with purulent discharge and localized pain.
View Article and Find Full Text PDFArterial and venous thromboembolic events in patients with cancer treated with targeted therapies: a population-based cohort study.
EClinicalMedicine
September 2025
Department of Clinical Epidemiology and Center for Population Medicine, Aarhus University Hospital and Aarhus University, Aarhus, Denmark.
Background: Emerging data suggest a substantial risk of arterial and venous thromboembolic events (ATE/VTE) associated with targeted cancer therapies. We examined the association between selected targeted therapies and ATE/VTE-risk using Danish population-based healthcare data.
Methods: We identified 41,744 patients with cancer treated with selected targeted therapies between January 2004 and December 2020.
Anti-Lung Cancer Effects and Related Mechanisms of α-Caryophyllene In Vitro and In Vivo.
Food Sci Nutr
September 2025
α-Caryophyllene is a natural condiment and flavoring additive. Herein, we first study the in vivo and in vitro anti-lung cancer efficacy of α-caryophyllene and its potential mechanism. In antitumor activity in vitro, α-caryophyllene exhibited obvious selective cytotoxicity, and its cytotoxicity against lung cancer A549 cells (IC = 22.
View Article and Find Full Text PDFAndrogen Receptor: Clinical Importance in Breast Cancer Patients Receiving CDK 4/6 Inhibitor Treatment.
Medicina (Kaunas)
August 2025
Department of Medical Oncology, Balikesir Ataturk City Hospital, Balikesir 10100, Turkey.
The effect of AR expression on prognosis in hormone receptor-positive her2-negative breast cancer is controversial. There are studies showing that AR is a treatment target, a mechanism of resistance to endocrine treatments, and a prognostic indicator in these patients whose standard treatment is a CDK 4/6 inhibitor added to endocrine treatment. We aimed to investigate the effect of AR, the AR/ER ratio, and the AR/PR ratio on CDK4/6 inhibitor treatment response in breast cancer, as well as their effects on PFS, and to validate the hypothesis that AR is a target for research.
View Article and Find Full Text PDFMultidisciplinary Practical Guidance for Implementing Adjuvant CDK4/6 Inhibitors for Patients with HR-Positive, HER2-Negative Early Breast Cancer in Canada.
Curr Oncol
August 2025
Department of Oncology, University of Calgary, Calgary, AB T2N 1N4, Canada.
Cyclin-dependent kinase (CDK)4/6 inhibitors have become a key component of adjuvant treatment for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer who are at high risk of recurrence. The addition of abemaciclib and ribociclib to standard endocrine therapy has demonstrated clinically meaningful improvements in invasive disease-free survival, supported by the monarchE and NATALEE trials, respectively. With expansion of patient eligibility for CDK4/6 inhibitors, multidisciplinary coordination among medical oncologists, surgeons, nurses, pharmacists, and other health care providers is critical to optimizing patient identification, monitoring, and management of adverse events.
View Article and Find Full Text PDF